Data Insights

FPI-1434 by Fusion Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Triple-Negative Breast Cancer (TNBC)

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Uveal Melanoma: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Uveal Melanoma

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Endometrial Cancer: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Endometrial Cancer

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Cervical Cancer: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Cervical Cancer

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Ovarian Cancer: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Ovarian Cancer

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Ewing Sarcoma: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Ewing Sarcoma

Data Insights

FPI-1434 by Fusion Pharmaceuticals for Solid Tumor: Likelihood of Approval

FPI-1434 is under clinical development by Fusion Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase...